Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients

被引:2
作者
Mathiesen, P. R. [1 ]
Zak, M. [2 ]
Herlin, T. [3 ]
Nielsen, S. M. [2 ]
机构
[1] Copenhagen Univ Hosp, Dept Paediat, Paediat Clin, DK-4300 Holbaek, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Paediat Rheumatol Unit, DK-4300 Holbaek, Denmark
[3] Aarhus Univ Hosp, Paediat Rheumatol Clin, Aarhus, Denmark
关键词
Juvenile dermatomyositis; outcome assessments; Myositis Damage Index; calcinosis; IDIOPATHIC INFLAMMATORY MYOPATHIES; NATIONAL-INSTITUTE; PROGNOSTIC-FACTORS; DISEASE; POLYMYOSITIS; ARTHRITIS; CHILDREN; DAMAGE; ONSET; MUSCULOSKELETAL;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess disease characteristics and outcome in Danish juvenile dermatomyositis (JDM) patients (1977-2007). Methods Medical record review of hospital records identified from the National Patient Register. Results Fifty-seven JDM patients were identified. Follow-up time was 7 years (range 0.06-30). Female:male ratio was 2.5:1. Mean age at disease onset was 7 years (SD +/- 3.7), range 1.5-16.0 years. Diagnostic delay was 0.7 years (SD +/- 1.6), range 0.04-9 years. Mean disease duration was 3.7 years (SD +/- 3.5), range 0.7-9 years. Thirty-nine patients (70%) were in full remission. Three patients (5%) were deceased. Disease/treatment-induced damage was present in 35 (61%) patients. Decreased pulmonary function occurred early in the disease course (median 10 months), osteoporosis and calcinosis occurred later (median 18 and 22 months). Four patients developed persistent damage within the first 6 months, four developed calcinosis within the first year. Shorter disease duration was associated with less damage (p=0.004). In a multivariate assessment analysis age > 10 years at disease onset was associated with more damage (p < 0.01), OR 10.96 (CI 1.6-73.6), and disease duration > 4 years was associated with calcinosis (p=0.01) OR 23.2 (CI 2.6-206.2). Conclusion We present a nationwide retrospective study of Danish JDM patients from 1977-2007. Although 70% were in remission, 61% of the patients had clinical signs of damage. Only a few patients developed damage within the first year of the disease. Longer disease duration and higher age at disease onset was correlated with more disease damage.
引用
收藏
页码:782 / 789
页数:8
相关论文
共 50 条
[41]   Long-Term Outcome and Prognostic Factors of Juvenile Dermatomyositis: A Multinational, Multicenter Study of 490 Patients [J].
Ravelli, Angelo ;
Trail, Lucia ;
Ferrari, Cristina ;
Ruperto, Nicolino ;
Pistorio, Angela ;
Pilkington, Clarissa ;
Maillard, Susan ;
Oliveira, Sheila K. ;
Sztajnbok, Flavio ;
Cuttica, Ruben ;
Beltramelli, Matilde ;
Corona, Fabrizia ;
Martha Katsicas, Maria ;
Russo, Ricardo ;
Ferriani, Virginia ;
Burgos-Vargas, Ruben ;
Magni-Manzoni, Silvia ;
Solis-Vallejo, Eunice ;
Bandeira, Marcia ;
Zulian, Francesco ;
Baca, Vicente ;
Cortis, Elisabetta ;
Falcini, Fernanda ;
Alessio, Maria ;
Alpigiani, Maria Giannina ;
Gerloni, Valeria ;
Saad-Magalhaes, Claudia ;
Podda, Rosanna ;
Silva, Clovis A. ;
Lepore, Loredana ;
Felici, Enrico ;
Rossi, Federica ;
Sala, Elena ;
Martini, Alberto .
ARTHRITIS CARE & RESEARCH, 2010, 62 (01) :63-72
[42]   Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study [J].
Dabbak, Imene ;
Rodero, Mathieu P. ;
Aeschlimann, Florence A. ;
Authier, Francois-Jerome ;
Bodemer, Christine ;
Quartier, Pierre ;
Bondet, Vincent ;
Charuel, Jean-Luc ;
Duffy, Darragh ;
Gitiaux, Cyril ;
Bader-Meunier, Brigitte .
RHEUMATOLOGY, 2022, 61 (11) :4514-4520
[43]   Update on the clinical management of juvenile dermatomyositis [J].
Huber, Adam M. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (12) :1021-1028
[44]   Juvenile Dermatomyositis-Clinical Phenotypes [J].
Li, Danyang ;
Tansley, Sarah L. .
CURRENT RHEUMATOLOGY REPORTS, 2019, 21 (12)
[45]   Juvenile Psoriatic Arthritis (JPsA) clinical features and outcome of 119 patients [J].
Y Butbul Aviel ;
PN Tyrrell ;
BM Feldman ;
RM Laxer ;
RK Saurenmann ;
L Spiegel ;
B Cameron ;
S Tse ;
ED Silverman .
Pediatric Rheumatology, 6 (Suppl 1)
[46]   Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis [J].
Sato, Satoshi ;
Uejima, Yoji ;
Nanbu, Meika ;
Suganuma, Eisuke ;
Takano, Tadamasa ;
Tanaka, Risa ;
Kabuki, Tomoyuki ;
Oguma, Eiji ;
Oh-Ishi, Tsutomu ;
Kawano, Yutaka .
MODERN RHEUMATOLOGY, 2017, 27 (04) :652-656
[47]   Dermatomyositis: Clinical features and pathogenesis [J].
DeWane, Madeline E. ;
Waldman, Reid ;
Lu, Jun .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) :267-281
[48]   Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis [J].
Rouster-Stevens, Kelly A. ;
Ferguson, Lori ;
Morgan, Gabrielle ;
Huang, Chiang-Ching ;
Pachman, Lauren M. .
ARTHRITIS CARE & RESEARCH, 2014, 66 (05) :783-787
[49]   Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists [J].
Mondal, Sanjib ;
Barman, Prabal ;
Vignesh, Pandiarajan .
FRONTIERS IN MEDICINE, 2022, 9
[50]   Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis [J].
Kishi, Takayuki ;
Warren-Hicks, William ;
Bayat, Nastaran ;
Targoff, Ira N. ;
Huber, Adam M. ;
Ward, Michael M. ;
Rider, Lisa G. .
RHEUMATOLOGY, 2021, 60 (05) :2134-2145